Abstract
Background
Methods
Results
REFERENCES
Table 1.
Characteristics | Value |
---|---|
Age (yr) | 52.6±12.4 (25-73) |
Male sex | 14 (64) |
Body mass index (kg/m2) | 19.9 (16.25-23.4) |
Smoker | 13 (59) |
Underlying lung disease | |
IPF | 12 (54) |
COPD | 1 (5) |
PPAH | 1 (5) |
AIP | 2 (9) |
Bronchiectasis | 2 (9) |
Post-SCT BOS | 3 (13) |
CVD-ILD | 1 (5) |
mMRC grade | |
II or III/IV | 9 (41)/13 (59) |
NYHA grade | |
II or III/IV | 7 (32)/15 (68) |
Comorbidity | 10 (45) |
Osteopenia/osteoporosis | 7 (32)/5 (23) |
25-Hydroxy vitamin D (ng/ml) | 9.0 (6.1-19.0) |
Pulmonary function | |
FVC (l) | 1.5 (1.1-2.4) |
FEV1 (l) | 1.1 (0.8-1.9) |
FEV1 (% predicted) | 43 (30-62) |
Cardiac function | |
LVEF (%) | 64 (58-68) |
Emergency statusa | |
Status 0 | 10 (45.5) |
Status 1 | 11 (50) |
Status 2 | 1 (4.5) |
Time on waiting list (day) | 35 (10-168) |
Donor age (yr) | 42.2±12.9 (16-59) |
Donor sex, male | 15 (68) |
Donor body mass index (kg/m2) | 22.8 (15.8-32) |
Donor PaO2/FiO2 | 428 (195-669) |
Preoperative status | |
Tracheostomy | 6 (27) |
Hospitalization | 3 (14) |
ICU care | 11 (50) |
Mechanical ventilator | 11 (50) |
ECMO support | 7 (32) |
Values are presented as mean±standard deviation (range), number (%), or median (interquartile range).
IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary disease; PPAH: primary pulmonary hypertension; AIP: acute interstitial pneumonia; SCT: stem cell transplantation; BOS: bronchiolitis obliterans syndrome; CVD-ILD: collagen vascular disease related interstitial lung disease; mMRC: modified Medical Research Council; NYHA: New York Heart Association; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; LVEF: left ventricular ejection fraction; PaO2: arterial partial pressure of oxygen; FiO2: fraction of inspired oxygen; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation.
Table 2.
Patient no. | Age (yr) | Sex | Diagnosis | Start of PR | Days of PR | Initial functional grade | Best functional grade | Final functional grade | O2 support at start of PR | O2 support at finish of PR | Status, survival months | Outcome (cause of death) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 54 | F | CVD-ILD | POD 14 | 10 | 4-2 | 4-3 | 4-3 | Nasal | Nasal | Alive, 14.8 | - |
2 | 63 | M | IPF | POD 7 | 48 | 2-1 | 4-2 | 4-2 | HFNC | Nasal | Alive, 16.0 | - |
3 | 46 | F | Bronchiectasis | POD 11 | 27 | 3-2 | 4-3 | 4-3 | Ventilator | Room air | Alive, 15.7 | - |
4a | 52 | M | IPF | POD 7 | 13 | 2-1 | 1-1 | 1-1 | T-mask | Ventilator | Died, 1.4 | Sudden cardiac arrest |
5 | 49 | F | AIP | POD 1 | 59 | 1-1 | 1-1 | 1-1 | Ventilator | Ventilator | Died, 2.9 | Bleeding |
6 | 32 | F | Post-SCT BOS | POD 8 | 217 | 3-1 | 4-2 | 4-2 | Ventilator | Room air | Alive, 14.6 | - |
7 | 62 | F | Bronchiectasis | POD 6 | 103 | 1-2 | 1-1 | 1-1 | Ventilator | Ventilator | Died, 4.0 | Pneumonia (Pseudomonas aeruginosa) |
8 | 26 | M | Post-SCT BOS | POD 6 | 85 | 1-2 | 3-2 | 3-2 | Nasal | Room air | Died, 12.7 | Sepsis (Acinetobacter baumannii) |
9 | 58 | F | IPF | POD 12 | 5 | 3-3 | 4-2 | 4-2 | Ventilator | Nasal | Died, 5.4 | Thrombotic thrombocytopenic purpura |
10 | 73 | M | IPF | POD 7 | 26 | 2-1 | 4-3 | 4-3 | Nasal | Room air | Died, 10.3 | Pneumonia (A. baumannii) |
11 | 58 | M | IPF | POD 1 | 14 | 1-1 | 4-2 | 4-2 | Nasal | Nasal | Died, 6.5 | Pneumonia (pathogen unknown) |
12 | 64 | M | IPF | POD 6 | 42 | 1-2 | 4-3 | 4-3 | Nasal | Room air | Alive, 13.4 | - |
13 | 60 | M | IPF | POD 6 | 59 | 1-2 | 3-1 | 3-1 | Ventilator | Ventilator | Died, 4.9 | Sepsis (A. baumannii) |
14 | 61 | M | COPD | POD 7 | 10 | 2-1 | 4-1 | 4-1 | Nasal | Nasal | Died, 5.6 | Pneumonia (A. baumannii) |
15 | 61 | M | IPF | POD 7 | 5 | 2-1 | 1-1 | 1-1 | Ventilator | Ventilator | Died, 1.5 | Sepsis (pathogen unknown) |
16 | 46 | M | AIP | POD 6 | 8 | 1-2 | 1-1 | 1-1 | Ventilator | Ventilator | Died, 2.6 | Sepsis (pathogen unknown) |
17 | 55 | F | IPF | POD 13 | 7 | 4-1 | 4-3 | 4-3 | Nasal | Nasal | Alive, 10.6 | - |
18 | 53 | M | IPF | POD 1 | 27 | 1-1 | 4-3 | 4-3 | Ventilator | Room air | Alive, 10.1 | - |
19 | 41 | M | Post-SCT BOS | POD 7 | 75 | 2-1 | 4-3 | 4-2 | Ventilator | Nasal | Alive, 9.4 | - |
20 | 25 | F | PPHN | POD 6 | 43 | 1-2 | 1-2 | 1-2 | Ventilator | Ventilator | Died, 2.3 | Sepsis (A. baumannii) |
21 | 60 | M | IPF | POD 7 | 42 | 2-1 | 4-3 | 4-3 | Nasal | Room air | Died, 5.5 | Sepsis |
22 | 58 | M | IPF | POD 8 | 10 | 3-1 | 4-3 | 4-3 | Nasal | Nasal | Alive, 7.0 | - |
PR: pulmonary rehabilitation; CVD-ILD: collagen vascular disease related interstitial lung disease; POD: postoperative day; IPF: idiopathic pulmonary fibrosis; HFNC: high flow nasal cannula; AIP: acute interstitial pneumonia; SCT: stem cell transplantation; BOS: bronchiolitis obliterans syndrome; COPD: chronic obstructive pulmonary disease; PPHN: primary pulmonary hypertension.